TLPH
Talphera Hits Milestone in Nephro CRRT Study, Strengthens Financial Position
In a significant development, Talphera, a leading biotechnology company, has announced that its Nephro CRRT study has reached the 50% enrollment milestone. This achievement, along with the satisfaction of certain conditions, triggered the closing of the third tranche of the company's March 2025 financing, generating gross proceeds of